Y-mAbs Announces Second Quarter Financial Results and Recent Corporate Developments

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. LMT
8. USO
9. META
10. TLT

Go back to Y-mAbs Announces Second Quarter Financial Results and Recent Corporate Developments

Y-mAbs Therapeutics (YMAB) Tops Q2 EPS by 11c

August 5, 2021 4:28 PM EDT

Y-mAbs Therapeutics (NASDAQ: YMAB) reported Q2 EPS of ($0.53), $0.11 better than the analyst estimate of ($0.64). Revenue for the quarter came in at $8.95 million versus the consensus estimate of $7.85 million.

We are very pleased with our second quarter 2021 results. The commercialization of DANYELZA® (naxitamab-gqgk) is... More